About Arium Biolabs
Arium Biolabs is a biotechnology company focused on advanced drug design and the engineering of enzymes for therapeutic, diagnostic, and industrial applications. Founded in 2018, the company was established to translate the latest scientific discoveries about how proteins and enzymes function into practical, high-impact solutions. Our mission is to harness modern biochemical insight and computational innovation to accelerate the development of safer, more effective technologies for human health and industry.
The company was founded by experts in biochemistry and high-performance computational methods, bringing together decades of combined experience in enzyme science, molecular simulation, and data-driven design. We are driven by rigorous scientific principles, a strong commitment to real-world impact, and the belief that the next generation of therapeutics will be shaped by a deep understanding of enzyme mechanisms. Above all, Arium Biolabs is committed to pioneering approaches that lead to safe, effective, and accessible medicines for patients and communities worldwide.
Our Mission
We are harnessing the power of enzyme engineering to address some of the most urgent challenges in healthcare and manufacturing. Through innovation, collaboration, and scientific excellence, we create biologically driven solutions capable of transforming how diseases are treated and how essential products are made. Our goal is to translate enzyme science into real-world impact—delivering technologies that improve lives, enhance safety, and advance human health.
What problem is Arium Biolabs currently solving?: Arium Biolabs’ immediate focus is the development of next-generation biotherapies for patients suffering from substance-use disorders, including addiction to natural and synthetic opioids such as fentanyl, as well as methamphetamine dependence. For many of these conditions, effective treatments simply do not exist, and the standard options available today—such as Methadone, Naloxone, and Buprenorphine—are far from optimal. Governments, healthcare providers, and families are urgently seeking new, highly effective therapeutic solutions for these “diseases of despair,” which impact millions of lives worldwide. The estimated market opportunity for improved opioid and stimulant addiction therapies alone is roughly $10 billion annually.
Beyond addiction medicine, Arium Biolabs’ core enzyme-engineering platform is fully applicable to treating a wide range of metabolic disorders. These conditions represent another substantial unmet need, with a global market estimated at $5–10 billion annually. By leveraging our foundational technology across these diverse applications, we aim to deliver novel therapies that address high-value medical challenges and offer meaningful benefits to patients.
Our Team
Dr. Pratul K. Agarwal — Founder & CEO
Founder • CEO • Enzyme Engineering & Computational Biology
Dr. Pratul K. Agarwal is a recognized expert in enzymology and computational methods, with advanced training from
IIT-Delhi, Penn State, and the University of Notre Dame. He has held senior leadership positions including Chief
Technology & Science Officer at the Oklahoma Pandemic Center and Associate Vice President of High-Performance
Computing at Oklahoma State University, and he previously led a research group at Oak Ridge National Laboratory.
Dr. Agarwal has authored over 90 peer-reviewed papers and is named on seven patents spanning enzyme science,
computational biology, and data analytics. His patented enzyme technologies have been licensed by industry
partners. He specializes in applying high-performance computing, molecular simulation, and machine learning to
accelerate enzyme design and therapeutic discovery.
While at Oak Ridge, he collaborated with an entrepreneur-in-residence from Foundation Capital to help
translate research into commercial impact.
Research Scientist — Biochemistry & Computational Biology
Our research scientists combine bench biochemistry with computational biology to validate enzyme designs and
translate in silico predictions into experimentally validated candidates. They are experienced in protein
expression, enzymology assays, and advanced molecular modeling.
Operations & Strategy — Industry and Regulatory Experts
Our operations and strategy team brings deep experience in clinical development, regulatory strategy, and
commercialization. They ensure we follow best practices for safety, compliance, and efficient product delivery,
and they shape business strategy for successful translation to market.
Anuj Jain — Intern, Computational Simulations & ML/AI
Anuj focuses on high-fidelity computational simulations and developing machine learning and AI approaches for
complex data analysis. His contributions accelerate the interpretation of simulation results and improve
predictive models used in enzyme engineering workflows.
We are a multidisciplinary team combining deep scientific expertise and practical industry experience to
advance enzyme-based solutions from concept to clinic and industry.
